Prevounce Health was recognized as a notable telehealth company for its cloud software, cellular-connected Pylo devices, and services that support remote patient monitoring and chronic care management.
Prevounce Health announced that patients have transmitted over 25 million vital readings using its Pylo remote monitoring devices. This milestone highlights the company's rapid growth and the increasing adoption of its connected care solutions.
A market report highlights the growth of the digital health monitoring sector and the increasing demand for remote patient monitoring. Prevounce is noted for its Pylo GL1-LTE device, which supports diabetes management programs.
Prevounce Health has introduced a new cellular-connected blood glucose meter designed for remote patient monitoring. This product expansion enhances the company's remote care management portfolio and clinical capabilities.
Following its relocation to Indianapolis, Prevounce announced a $4.5 million Series A funding round. The company stated plans to use the capital to scale operations and double its workforce.
Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →